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Abstract
OBJECTIVE: H1N1 was a new and potentially seri-
ous infectious disease, in human, the severity of in-
fluenza can vary from mild to severe, thus to find
an effective and safety way to control the influenza
pandemic is of crucial importance. This retrospec-
tive study describes the duration of viral shedding
in H1N1 patients that were hospitalized and treat-
ed in China.
METHODS: Clinical data were collected from May
to July, 2009 in China for 963 patients with influen-
za A (H1N1) virus infection. Patients were treated
based on the guidelines issued by the Chinese Min-
istry of Health. The primary outcome was duration
of viral shedding and statistical comparisons were
performed.
RESULTS: In the patients with body temperature
greater than 38.0°C, there were no differences in vi-
rus shedding duration among the patients taking
oseltamivir within two days, patients undergoing
Traditional Chinese Medicine (TCM) therapy or
those receiving no drug therapy. In patients with
body temperature ³38.1° C, TCM therapy reduced
the viral shedding duration (P<0.05, vs. oseltamivir
therapy). Furthermore, taking oseltamivir two days
after onset of symptoms might prolong the virus
shedding duration (P<0.05, vs. taking oseltamivir
less than 2 days of onset).
CONCLUSION: TCM therapy is effective for reduc-
ing the length of virus shedding in patients with
body temperature ³38.0°C. Oseltamivir used for re-
ducing virus shedding duration should be taken
within two days of onset.
© 2012 JTCM. All rights reserved.
Key words: H1N1; Treatment of oseltamivir; Treat-
ment of TCM
INTRODUCTION
The Chinese government has taken important steps for
the prevention and treatment of 2009 pandemic influ-
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enza A (H1N1, abbreviated as H1N1 pdm in this pa-
per) virus infection. Two teams of experts from biomed-
icine and Traditional Chinese Medicine (TCM) were
organized to generate guidelines for the prevention and
treatment of H1N1 virus infection[1]. While the clinical
characteristics of the 2009 H1N1 pdm virus infection
in China have been previously reported[2], the effect of
recommended treatment guidelines has yet to be ascer-
tained by a retrospective study on collected cases for
guiding future treatment strategies.
Since H1N1 was a new and potentially serious infec-
tious disease, a network of hospitals that specialize in
infectious diseases was formed to quarantine and treat
patients infected with H1N1 virus. Beijing Ditan Hos-
pital, one of the hospitals in this network, collected
clinical data from H1N1 infected patients, as well as
from patients with H1N1 at other hospitals in the net-
work. There is little knowledge about how to treat such
a new and potential serious infectious disease; thus, a
retrospective analysis of clinical data would be helpful
for future treatment strategies and exploring new thera-
pies for the disease. The current retrospective study in-
vestigated the duration of viral shedding in 963 cases
of H1N1 virus infection that were treated with differ-
ent therapies from May to July, 2009 to determine the
period of maximum transmission of the virus.This
study was approved by the appropriate ethics commit-
tees and was performed in accordance with the ethical
standards laid down in the Declaration of Helsinki. All
persons signed their informed consent prior to their in-
clusion in the study.
METHODS
Patients
This retrospective study was conducted using data col-
lected for 963 hospitalized patients who were recruited
in eight hospitals, including Beijing Ditan Hospital af-
filiated with Capital Medical University, Beijing Youan
Hospital affiliated with Capital Medical University,
The Eighth Guangzhou Hospital, Chengdu Conta-
gious Disease Hospital, The Second Hospital affiliated
with Guangzhou University of Chinese Medicine, Peo-
ple's Hospital in Linyi of Shandong Province, People's
Hospital in Liao City of Shandong Province, and Xinji-
ang Uygur Autonomous Region Contagious Disease
Hospital. H1N1 infection was confirmed by real-time
reverse transcription polymerase chain reaction
(RT-PCR) assay performed at the Laboratory of Insti-
tute of Infectious Disease in Ditan Hospital operated
under the auspices of the Chinese Center for Disease
Control and Prevention. Patient characteristics are list-
ed in Table 1. Symptoms and signs for each patient
were recorded daily. Details of all treatments were re-
corded. Daily pharyngeal or nasopharyngeal swabs
were analyzed for the presence H1N1 virus using re-
al-time RT-PCR testing. All clinical data were sent to
and stored at Beijing Ditan Hospital from May to July,
2009 as a secured file.
Table 1 Patient characteristics
Characteristic
Number of cases
Male sex-no.(%)
Age-yr: Mean±sd
Age group-no.(%)
<5 yr
5-14 yr
15-30 yr
31-50 yr
51-65 yr
>65 yr
Body temperature-no (%)*
<37.3 °C
37.3-38.0 °C
38.1-39.0 °C
Oseltamivir
in 2 days
172
97(56.4)
23.08±14.56
4(2.33)
52(30.23)
77(44.77)
29(16.86)
8(4.65)
2(0.16)
65(38.69)
45(26.79)
40(23.81)
Oseltamivir
after 2 days
96
50(52.08)
21.43±11.87
4(4.17)
19(19.79)
63(65.63)
6(6.25)
4(4.17)
0
56(58.95)
21(22.11)
15(15.79)
Oseltamivir
in 2 days
plus TCM
256
150(58.59)
22.96±13.36
6(2.34)
63(24.61)
137(53.52)
35(13.67)
14(5.47)
1(0.39)
65(26.32)
87(35.22)
79(31.98)
Oseltamivir
after 2 days
plus TCM
134
67(50)
22.54±13.75
3(2.24)
41(30.60)
56(41.79)
31(23.13)
2(1.49)
1(0.75)
57(44.19)
41(31.78)
25(19.38)
TCM
208
113(54.33)
20.25±11.79
1(0.48)
76(36.54)
100(48.08)
25(12.02)
5(2.40)
1(0.48)
121(58.17)
50(24.04)
27(12.98)
No therapy
97
44(45.36)
18.46±10.11
2(2.06)
36(37/11)
47(48.45)
11(11.34)
1(1.03)
0
69(71.13)
20(20.62)
6(6.19)
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>39.0°C
Duration of fever
18(10.71)
1.94±1.04
3(3.16)
1.56±0.68
16(6.48)
1.76±0.85
6(4.65)
1.58±0.64
10(4.81)
1.82±1.09
2(2.06)
1.39±0.5
Notes: Oseltamivir used within two days (oseltamivir within two days), oseltamivir used two days after onset (oseltamivir after two days),
TCM therapy (TCM), oseltamivir used in two days with TCM therapy (oseltamivir within two days plus TCM), oseltamivir used after
two days with TCM therapy (oseltamivir after two days plus TCM), no drug therapy (No therapy). *P<0.001 among the cases treated with
different therapies.
Real-time RT-PCR
The 2009 H1N1 pdm virus was detected using a re-
al-time RT-PCR assay in accordance with the protocol
from the United States Centers for Disease Control
and Prevention (CDC), as recommended by the World
Health Organization (WHO) [3]. The PCR products
were sequenced using the BigDye Terminator, version
3.1 Cycle Sequencing Kit (Applied Biosystems, Carls-
bad, CA) in accordance with the manufacturer's in-
structions.
Treatments
Two guidelines were used by physicians to direct treat-
ment: 1) the National Diagnostic and therapeutic
Guidelines for H1N1 Influenza A (published on May
9, 2009) [4] were adapted from guidelines provided by
the CDC; and 2) guidelines on prevention and treat-
ment with TCM issued by the State Administration of
Traditional Chinese Medicine[5]. Physicians used these
guidelines and clinical experience to make treatment
decisions. Generally, for patients with elevated fever
(body temperature between 38.1-38.9°C), only oselta-
mivir or TCM therapy was used. For the patients with
higher fever (body temperature ³39.0° C), combined
therapy (oseltamivir and TCM) was used. Some pa-
tients with no or mild fever were not treated with drug
therapy. For the recommended dosage, 75 mg oseltami-
vir was administered orally, twice a day. For TCM treat-
ment, 20 mL Shuang Huang Lian liquor (Sanjing Phar-
maceutical, Harbin, China) that contains Flos lonicer-
ae, Radix scutellariae, Fructus forsythiae, was adminis-
tered orally three times a day, four Lian Hua Qing
Wen capsules (Hebei Yiling Pharmaceutical, Hebei,
China; Fructus forsythiae, Flos lonicerae, honey-fried
herba ephedrae, fried Semen armeniacae amarum, Gyp-
sum fibrosum, Radix isatidis, cyrtomii rhizoma, Herba
Houttuyniae, Herba Pogostemonis, Radix et Rhizoma
Rhei, integripetal rhodiola herb, Mentholum, Radix
Glycytthizae) were administered orally four times a
day, and four Shu Feng Jie Du capsules (Anhui Jiren
Pharmaceutical, Anhui Province, China; Rhizoma
Polygoni Cuspidati, Fructus forsythiae, Dahurian pa-
trinia herb, Herba Verbanae, Radix Glycytthizae, Radix
Isatidis, Radix bupleuri, Rhizoma Phragmitis) was ad-
ministered orally, three times daily. All TCM products
were manufactured by pharmaceutical companies that
were GMP(Good Manufacturing Practice) certified, of-
ficially marketed in China for at least three years and
approved by the Chinese State Food and Drug Admin-
istration. A total of 598 cases were administered TCM
products. Among these cases, 416 were administered
two treatments at same time, and 182 were only ad-
ministered one. Additionally, 390 cases were adminis-
tered a TCM product plus oseltamivir at same time.
According to TCM with similar pharmacological activi-
ty (even with different composition of herbs), patients
that were administered a TCM product were treated as
cases treated with TCM therapy. No further stratifica-
tion based on different TCM products was conducted
in this study since physicians also believed that the
TCM products have similar activity.
Evaluation of efficacy
Since controlling viral spread was an important goal of
H1N1 treatment, the duration of viral shedding was
used to evaluate treatment efficacy. The duration of vi-
ral shedding was defined as the time period from the
day of symptom onset to day with negative results by
RT-PCR from two consecutive pharyngeal or nasopha-
ryngeal swabs.
Data analysis
Continuous variables were summarized as means±stan-
dard deviation (SD). For categorical variables, the per-
centages of patients in each category were calculated.
Clinical characteristics were compared among groups
of patients with different therapies with the use of an
analysis of variation (ANOVA) test, chi-square test, or
Fisher's exact test, as appropriate. The differences in
the duration of viral shedding among patients treated
with different therapies were analyzed using ANOVA
test and least significant difference (LSD) methods. A
previous study showed that treatment with oseltamivir
for less than two days might reduce the duration of vi-
ral shedding[2]. In this study, the intervals with less than
or greater than two days between symptom onset and
initiation of oseltamivir therapy were used as a stratifi-
cation factor. Since body temperature was used to de-
termine treatment (TCM therapy and/or oseltamivir),
body temperature was used as a stratification factor for
the analyses.
Symptoms and signs might be also used as the parame-
ters to choose appropriate therapeutic approaches. Mul-
tiple logistic-regression analysis was used to identify in-
dependent predictors of viral shedding duration from
all symptoms and signs among all patients. The inde-
pendent predictors were also used as stratification fac-
tors in the analysis. All analyses were performed using
SAS (Version 9.1.3; SAS Institute, Cary, NC). A P-val-
ue of <0.05 was considered statistically significant.
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RESULTS
Patient characteristics
Table 1 shows that body temperature was the only dif-
ference in the baseline characteristics of patients treated
with different therapies. Thus, body temperature was
used as a stratification factor in subsequent analyses. Ta-
ble 2 shows that there were some differences in the fre-
quency of symptoms and signs in the cases treated with
different therapies. Cases treated with oseltamivir +
TCM within two days of onset and those treated with
oseltamivir + TCM after two days of onset showed a
higher frequency of sore throat. Cases treated with osel-
tamivir within two days and those treated with no
drug therapy showed lower frequency of myalgia (ar-
thralgia). Cases treated with no drug therapy and osel-
tamivir in two days showed a lower frequency of nasal
congestion. Cases treated with no drug therapy showed
lower frequency of tensile swelling. These symptoms
and signs were also used as stratification factors in sub-
sequent analyses.
Table 2 Frequency of symptoms and signs in cases treated with different therapies
Symptom
and Sign
Cough
Sore throat*
Sputum production
Rhinorrhea
Headache
Nasal congestion#
Myalgia,arthralgia@
Chill
Conjunctival congestion
Diarrhea
Nausea,vomiting
Chest pain
Swelling of tonsils$
Enlargement of lymph
nodes
Stomachache
Dyspnea
Oseltamivir
in 2 days
104/172(60.47)
49/172(28.49)
41/172(23.84)
28/172(16.28)
31/172(18.02)
17/172(9.88)
10/172(5.81)
10/172(5.81)
0/172(0)
2/172(1.16)
5/172(2.91)
0/172(0)
61/172(35.47)
0/172(0)
0/172(0)
2/172(1.16)
Oseltamivir
after 2 days
73/96(76.04)
42/96(43.75)
25/96(26.04)
30/96(31.25)
20/96(20.83)
20/96(20.83)
7/96(7.29)
8/96(8.33)
2/96(2.08)
1/96(1.04)
0/96(0)
2/96(2.08)
25/96(26.04)
1/96(1.04)
0/96(0)
0/96(0)
Oseltamivir
in 2 days plus TCM
193/256(75.39)
117/256(45.7)
67/256(26.17)
43/256(16.8)
44/256(17.19)
37/256(14.45)
38/256(14.84)
24/256(9.38)
4/256(1.56)
6/256(2.34)
6/256(2.34)
0/256(0)
102/256(39.84)
0/256(0)
4/256(1.56)
1/256(0.39)
Oseltamivir
after 2 days
plus TCM
100/134(74.63)
60/134(44.78)
43/134(32.09)
30/134(22.39)
15/134(11.19)
19/134(14.18)
11/134(8.21)
7/134(5.22)
4/134(2.99)
5/134(3.73)
5/134(3.73)
2/134(1.49)
51/134(38.06)
1/134(0.75)
1/134(0.75)
0/134(0)
TCM
152/208(73.08)
80/208(38.46)
54/208(25.96)
55/208(26.44)
31/208(14.9)
31/208(14.9)
16/208(7.69)
16/208(7.69)
0/208(0)
4/208(1.92)
10/208(4.81)
1/208(0.48)
73/208(35.1)
0/208(0)
3/208(1.44)
4/208(1.92)
No therapy
63/97(64.95)
28/97(28.87)
20/97(20.62)
21/97(21.65)
11/97(11.34)
6/97(6.19)
4/97(4.12)
4/97(4.12)
2/97(2.06)
1/97(1.03)
0/97(0)
0/97(0)
22/97(22.68)
1/97(1.03)
0/97(0)
1/97(1.03)
P value
0.0071
0.0014
0.4841
0.0121
0.2558
0.0441
0.0053
0.4480
0.0953
0.5806
0.0885
0.0826
0.0226
0.2997
0.3389
0.3243
Notes: Data are presented as positive no./total no. (%). Oseltamivir used within two days (oseltamivir in two days), oseltamivir used two
days after onset (oseltamivir after two days), TCM therapy (TCM), oseltamivir used in two days with TCM therapy (oseltamivir within
two days plus TCM), oseltamivir used after two days with TCM therapy (oseltamivir after two days plus TCM), no drug therapy (No
therapy). *P=0.0014. Cases treated with oseltamivir in two days plus TCM, and oseltamivir after two days plus TCM showed higher
frequency of sore throat. @ P=0.0053. Cases treated with oseltamivir in two days and no drug therapy showed lower frequency of myalgia
(arthralgia). #P=0.0441. Cases treated with no drug therapy and oseltamivir in two days showed lower frequency of nasal congestion. $P=
0.0226. Cases treated with no drug therapy showed lower frequency of swelling of tonsils.
Duration of viral shedding
Body temperature was determined to be a key clinical
sign for physicians to choose therapy, and Table 1
shows a difference in body temperature among patients
treated with different therapies. Thus, body tempera-
ture at onset of therapy was one of the most important
stratification factors for this retrospective analysis on vi-
ral shedding duration.
Figure 1 shows that no difference in the duration of vi-
ral shedding was observed in cases with normal body
temperature treated with oseltamivir within two days
and no drug therapy. However, the use of oseltamivir
after two days from symptom onset (including oselta-
mivir and TCM) was shown to be associated with pro-
longed virus shedding duration. Similarly, Figure 1 also
shows that there was no difference in the duration of vi-
ral shedding in cases with body temperature ³37.3°C
treated with oseltamivir within two days, TCM thera-
py and no drug therapy, and the use of oseltamivir af-
ter two days from onset (including oseltamivir and
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TCM) was associated with prolonged virus shedding
duration. These data suggest that patients with normal
body temperature or ³37.3°C should be treated with
either oseltamivir within two days of symptom onset
or just rest with no drug therapy, and administration of
oseltamivir after two days from onset was not an effec-
tive treatment.
Table 1 shows that the body temperature in most cases
treated with no drug therapy were normal or <38.0°C.
Thus, the stratification based on body temperature <
38.0° C was used for subsequent analyses. Similar to
the data presented in Figure 1, the use of oseltamivir af-
ter two days from onset does not reduce the duration
of viral shedding.
Figure 2 shows that the duration of viral shedding in
the cases with body temperature ³38.1°C treated with
TCM was shorter than those treated with oseltamivir
within two days (P<0.05). These findings suggest that
patients with body temperature ³38.1°C could be effec-
tively treated with TCM to reduce the duration of viral
shedding.
Oseltamivir application
Figure 3 shows that the duration of viral shedding in
cases treated with oseltamivir within two days was
shorter than those treated with oseltamivir after two
days in cases with normal body temperature or body
temperature ³37.3°C. These results further support the
finding that taking oseltamivir within two days from
disease onset is more effective at reducing viral shed-
ding duration in patients either with a normal body
temperature or body temperature ³37.3°C.
Alleviation of symptoms and signs
Alleviation of symptoms and signs is also an important
parameter used to evaluate the effect of administered
therapies. After analyzing the duration of symptoms
and signs, analyses revealed that there was no differ-
ence in reducing the duration of the symptoms and
signs among cases treated with different therapies if the
patients were stratified by body temperature (data not
shown).
Rare adverse events were observed. Two cases treated
with oseltamivir and TCM developed abnormal liver
function tests. Two cases treated with oseltamivir devel-
oped an allergic reaction. One case treated with TCM
developed nausea and vomiting. Two cases treated with
TCM and one case treated with oseltamivir developed
a rash.
Effect of symptoms and signs on the duration of virus
shedding
Symptoms and signs might be taken as indications for
the application of different therapies. Table 2 shows
that there were differences in the frequency of some
symptoms and signs in cases treated with different ther-
apies, that included sore throat, myalgia (arthralgia),
nasal congestion, and tonsillitis. In order to analyze
whether the symptoms and signs influenced the dura-
tion of viral shedding caused by different therapies,
multiple logistic-regression analysis was used to identi-
fy independent predictors of viral shedding duration
among all patients by analyzing the predicted roles of
age, sex, and all symptoms and signs (Table 2) for dura-
tion of viral shedding (5 days as risk point). Table 3
shows that patients aged <14 years old, sputum produc-
tion, nasal congestion, or sore throat were found to be
predictors for longer (>5 days) duration of viral shed-
ding. Myalgia (arthralgia) and tonsillitis was not predic-
tive of the duration of viral shedding. Thus, age, spu-
tum production, sore throat, and nasal congestion were
used as stratification factors in subsequent analyses of
the duration of viral shedding in the patients treated
with different therapies. No difference were observed
for these four predictors among patients treated with
different therapies (data not shown) and the predictors
were not related to differences in viral shedding dura-
tion among the patients treated with different thera-
pies.
DISCUSSION
Here we report a retrospective analysis of 963 patients
hospitalized with the 2009 H1N1pdm virus infection
between May and July of 2009 in China. Our major
findings include that the use of oseltamivir within two
days of onset of symptoms or TCM therapy in patients
with normal body temperature does not significantly
reduce the duration of viral shedding. Compared to
those no treated with drug therapy, TCM therapy was
shown to reduce virus shedding duration in patients
with body temperature ³38.1°C, and taking oseltami-
vir after two days of onset of symptoms might prolong
virus shedding duration, even when compared to no
drug therapy. These findings are similar to a previous
study on the timing of oseltamivir use [2,6-8].
TCM with its natural products has been shown to have
good therapeutic effect for the treatment of seasonal in-
fluenza [9,10]. At the beginning of the 2009 H1N1 pdm
virus infection epidemic in China, a team of TCM doc-
tors evaluated infected patients and developed expert
consensus guidelines for the use of TCM therapy for
treating H1N1 infection, and were issued by the State
Administration of Traditional Chinese Medicine[1]. In
the guidelines, Shuang Huang Lian Liquor, Lian Hua
Qing Wen capsule, and Shu Feng Jie Du capsule were
selected as the recommended herbal products for treat-
ment of influenza. In cases treated with TCM therapy
(including combination with oseltamivir therapy),
more than 92% patients were given a single herbal
product, either Shuang Huang Lian Liquor, Lian Hua
Qing Wen capsule, or Shu Feng Jie Du capsule thera-
py, and only 8% patients were given a combination of
two of the three herbal medicines. The current study
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showed that TCM therapy could be a better choice for
reducing the duration of viral shedding for patients
with elevated body temperature (>38.0°C). These data
suggest that TCM can be an effective therapy for reduc-
ing the transmission of the 2009 H1N1 pdm virus in-
fection in China. Moreover, increasing resistance to os-
eltamivir among influenza A (H1N1) strains could lim-
it the efficacy of treatment with oseltamivir[11-13], and in
such a case, TCM therapies may be an alternative thera-
py for reducing the spread of influenza.
In clinical practice, physicians believe that if patients
demonstrate an elevated body temperature and/or
more symptoms and signs of infection, they should be
treated with a combination of oseltamivir and TCM[1].
However, our data do not demonstrate the advantage
for the use of combination therapy for the reduction of
the viral shedding duration. These findings suggest
that there needs to be more data to support the use of
integrative medicine therapy (both TCM and oseltami-
vir) in the pandemic influenza A patients.
Table 3 Independent predictors of viral shedding duration obtained by multiple logistic-regression analysis
Variable
Age: <14 yrs vs > or equal to 14 yrs
Sputum production: without vs with
Sore throat: without vs with
Nasal congestion: without vs with
Odds Ratio (95% CI)
1.54 (1.07-2.20)
0.64 (0.44-0.92)
0.63 (0.45-0.88)
0.53 (0.31-0.91)
P value
0.01962
0.016084
0.006291
0.020932
Figure 1 Duration of viral shedding in cases with normal body temperature (upper panel), and duration of viral shedding in the
cases with body temperature³37.3 °C (lower panel). Data are shown as mean±SD. Six therapies are listed: oseltamivir used within
two days (Oseltamivir within two days), oseltamivir used two days after onset (Oseltamivir after two days), TCM therapy, oseltami-
vir used in two days with TCM therapy (Oseltamivir within two days plus TCM), oseltamivir used after two days with TCM therapy
(Oseltamivir after two days plus TCM), no drug therapy (No therapy). Case numbers and means are listed on the right. In the up-
per panel, * P<0.05 (Oseltamivir within two days, No therapy vs Oseltamivir after two days); #P<0.05 (Oseltamivir in two days vs. Os-
eltamivir after two days + TCM). In the lower panel, *P<0.05 (TCM therapy vs. oseltamivir after two days and oseltamivir after two
days plus TCM); #P<0.05 (Oseltamivir within two days vs oseltamivir after 2 days and oseltamivir after two days plus TCM).
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Figure 2 Duration of viral shedding in cases with body temperature ³38.1°C. Data are shown as mean±SD. Six therapies are listed:
oseltamivir used in two days (Oseltamivir within two days), oseltamivir used two days after onset (Oseltamivir after two days),
TCM therapy, oseltamivir used in two days with TCM therapy (Oseltamivir within two days plus TCM), oseltamivir used after two
days with TCM therapy (Oseltamivir after two days plus TCM), no drug therapy (No therapy). The case numbers and means are list-
ed on the right. * P<0.05 (TCM therapy vs. Oseltamivir in two days, Oseltamivir within two days plus TCM, Oseltamivir after two
days, Oseltamivir after two days plus TCM).
Figure 3 Duration of viral shedding in cases treated with oseltamivir. Data are shown as mean±SD. All patients treated with oselta-
mivir (including oseltamivir with TCM) were included. The therapies included oseltamivir used in two days (Oseltamivir within two
days), oseltamivir used after two days (Oseltamivir after two days) listed on the left. Case numbers and means are listed on the
right. *P<0.05 (Oseltamivir within two days vs. Oseltamivir after two days).
It has been assumed that some symptoms and signs,
which might reflect the severity of the disease, could in-
fluence the duration of viral shedding[1]. We found
some symptoms and signs (Table 3) were associated
with the duration of viral shedding in multiple logis-
tic-regression analysis. However, using these predictors
as stratification factors in subsequent further analyses,
we did not find that symptoms and signs had an effect
on viral shedding duration, which indicated that the
correlation between these symptoms and signs and du-
ration of viral shedding couldn't be confirmed in this
study.
The major limitation of this study was that all data
were collected retrospectively, thus a randomized-con-
trolled clinical study must be conducted to confirm
these findings. However, for this emerging infectious
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disease, our present findings may be helpful for improv-
ing the design of future clinical trials, particularly with
regard to stratification of patients, and oseltamivir and
TCM therapy application. Another limitation of this
study was that there are currently three TCM products
used for TCM therapy, and it was difficult to define
further sub-groups for different TCM products since at
least nine different combinations of clinical data exist-
ed. Thus, focusing on one or two fixed TCM formulae
in future clinical trials would better evaluate the effect
of TCM therapy for the patients despite similar activi-
ties.
In conclusion, TCM or oseltamivir therapy or combi-
nations thereof, do not reduce the duration of viral
shedding in the patients with normal body tempera-
ture, and TCM therapy can be effective in patients
with a body temperature >38.0° C. Furthermore, the
use of oseltamivir two days after onset of clinical signs
can prolong the viral shedding duration.
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